Item 2.02 Results of Operations and Financial
Conditions.
On March 16, 2020, Immunic, Inc. (the “Company”
or “Immunic”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s
financial results for the quarter and year ended December 31, 2019 and providing a corporate update (the “Press Release”).
The information contained in Item 2.02 of this Current Report
on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s
filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.
Cautionary Note Regarding Forward-Looking Statements
Certain statements in this communication and the Press Release
are forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995.
The Press Release contains “forward-looking statements”
that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation
Reform Act of 1995. All statements, other than statements of historical facts, included in the Press Release regarding strategy,
future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management
are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic’s
three development programs and the targeted diseases; the potential for IMU-838, IMU-935 and IMU-856 to safely and effectively
target diseases; preclinical data for IMU-856; the timing of future clinical trials; the nature, strategy and focus of the company;
and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans,
carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not
place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations
and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking
statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project
future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient
resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may
not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic’s intellectual
property, risks related to the drug development and the regulatory approval process and the impact of competitive products and
technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section
captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2019, filed with the SEC on March 16, 2020, and in the company’s subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov or ir.immunic-therapeutics.com/sec-filings and on request from Immunic.
The statements made in this Current Report on Form 8-K and the
Press Release speak only as of the date stated herein, and subsequent events and developments may cause the Company’s expectations
and beliefs to change. While the Company may elect to update these forward-looking statements publicly at some point in the future,
the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise,
except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views
as of any date after the date stated herein.